曲美他嗪治疗冠心病合并心律失常的疗效观察  

The effect of trimetazidine on coronary heart disease combined with arrhythmia

作　　者：郑文权[1] 张昀昀[2] 林群峰[1] 张洁[1] 

机构地区：[1]上海交通大学附属第六人民医院奉贤分院心内科,上海201400 [2]上海交通大学附属第六人民医院心内科,上海200233

出　　处：《世界临床药物》2009年第6期351-353,共3页World Clinical Drug

摘　　要：目的观察曲美他嗪对已接受常规治疗的冠心病合并心律失常患者的疗效。方法81例明确诊断为冠心病合并心律失常的患者随机分为两组,对照组(n=39)接受常规治疗,治疗组(n=42)在对照组基础上加用曲美他嗪一日3次,每次20mg餐后口服。治疗前及治疗后分别行静息心电图、24h动态心电图、血常规、尿常规、肝功能及肾功能等检查。以静息心电图及24h动态心电图的改变为疗效判定依据,以患者主诉及肝功能、肾功能等实验室检查结果为不良反应观察指标。结果与对照组相比,治疗组心电图缺血性ST-T改变显著改善,心律失常显著减少,差异具有统计学意义(P<0.05)。两组均未见严重药物不良反应。结论曲美他嗪用于冠心病合并心律失常患者治疗有效而安全,改善心肌缺血可能是其主要作用基础。Objective To observe the effect of trimetazidine on coronary heart disease combined with arrhythmia. Methods Eighty-one patients were randomly divided into treatment group （n = 42） and control group（n = 39）. Patients in the control group received routine therapy and patients in the treatment group took trimetazidine orally 20 mg three times per day on the basis of routine therapy. Resting electrocardiogram （ECG）, Halter, blood routine, urine routine, liver function and renal function were detected before and after treatment. Changes of resting ECG and Halter were used to evaluate the curative effect. Present symptoms and the results of laboratory examinations were used to evaluate the adverse reactions. Results Compared with the control group, the ischemic ST-T of ECG improved significantly and the numbers of arrhythmia decreased significantly in the treatment group （P 〈 0.05）. There was no difference in the adverse reactions between two groups. Conclusion Trimetazidine may be used effectively and safely in patients with coronary heart disease complicating arrhythmia.

关 键 词：曲美他嗪 冠状动脉疾病 心律失常 

分 类 号：R543.3[医药卫生—心血管疾病] R972[医药卫生—内科学]